中国肝静脉压力梯度临床应用专家共识（2018年版）

doi:10.3969/j.issn.1672-5069.2019.03.005

[1] Qi X,Berzigotti A,Cardenas A,Sarin SK.Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol,2018,3(10):708-719.
[2] Bosch J,Abraldes JG,Berzigotti A,et al.The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol,2009,6(10):573-582. DOI:10.1038/nrgas-tro.2009.149.
[3] Wang FS,Fan JG,Zhang Z,Gao B,Wang HY.The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108.DOI:10.1002/hep.27406.
[4] Mokdad AA,Lopez AD,Shahraz S,et al.Liver cirrhosis mortality in 187 countries between1980 and 2010:a systematic analysis[J]. BMC Medicine,2014,12:145. DOI:10.1186/s12916-014-0145-y.
[5] Estes C,Anstee QM,Teresa Arias-Loste M,et al. Modeling NAFLD disease burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the period2016-2030[J]. J Hepatol,2018. In press. DOI:10.1016/j.jhep.2018.05.036.
[6] Wang X,Lin SX,Tao J,et al.Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol,2014,20(37):13546-13555. DOI:10.3748/wjg.v20.i37.13546.
[7] Groszmann RJ,Wongcharatrawee S.The hepatic venous pressure gradient:anything worth doing should be done right[J]. Hepatology,2004,39(2):280-282. DOI:10.1002/hep.20062.
[8] Abraldes JG,Sarlieve P,Tandon P.Measurement of portal pressure[J]. Clin Liver Dis,2014,18(4):779-792. DOI:10.1016/j.cld.2014.07.002.
[9] de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol,2005,43(1):167-176. DOI:10.1016/j.jhep.2005.05.009.
[10] de Franchis R;Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752. DOI:10.1016/j.jhep.2015.05.022.
[11] Garcia-Tsao G,Abraldes JG,Berzigotti A,et al.Portal hypertensive bleeding in cirrhosis:risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology,2017,65(1):310-335. DOI:10.1002/hep.28906.
[12] Merkel C,Montagnese S.Hepatic venous pressure gradient measurement in clinical hepatology[J]. Digest Liver Dis,2011,43(10):762-767. DOI:10.1016/j.dld.2011.03.002.
[13] Tey TT,Gogna A,Irani FG,et al.Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics[J]. Singapore Med J,2016,57(3):132-137. DOI: 10.11622/smedj.2016054.
[14] 王吉耀,王强,王小钦,等. 中国临床实践指南评价体系的制定与初步验证[J]. 中华医学杂志,2018,98(20):1544-1548. DOI:10.3760/cma.j.issn.0376-2491.2018.20.004.
[15] Guyatt GH,Oxman AD,Vist GE,et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendation[J]. BMJ,2008,336(7650):924-926. DOI:10.1136/bmj.39489.470347.AD.
[16] Balshem H,Helfand M,Schünemann HJ,et al.GRADE guidelines:3. Rating the quality of evidence[J]. J Clin Epidemiol,2011,64(4):401-406. DOI:10.1016/j.jclinepi.2010.07.015.
[17] Guyatt GH,Oxman AD,Schünemann HJ,et al.GRADE guidelines:a new series of articles in the Journal of Clinical Epidemiology[J]. J Clin Epidemiol,2011,64(4):380-382. DOI:10.1016/j.jclinepi.2010.09.011.
[18] Guyatt GH,Oxman AD,Vist G,et al.GRADE guidelines:4. Rating the quality of evidence-study limitations (risk of bias)[J]. J Clin Epidemiol,2011,64(4):407-415. DOI:10.1016/j.jclinepi.2010.07.017.
[19] Guyatt GH,Oxman AD,Montori V,et al.GRADE guidelines:5. Rating the quality of evidence-publication bias[J]. J Clin Epidemiol,2011,64(12):1277-1282.DOI:10.1016/j.jclinepi.2011.01.011.
[20] Guyatt GH,Oxman AD,Kunz R,et al.GRADE guidelines:6. Rating the quality of evidence-imprecision[J]. J Clin Epidemiol,2011,64(12):1283-1293. DOI:10.1016/j.jclinepi.2011.01.012.
[21] Guyatt GH,Oxman AD,Kunz R,et al.GRADE guidelines:7. Rating the quality of evidence-inconsistency[J]. J Clin Epidemiol,2011,64(12):1294-1302. DOI:10.1016/j.jclinepi.2011.03.017.
[22] Guyatt GH,Oxman AD,Kunz R,et al.GRADE guidelines:8. Rating the quality of evidence-indirectness[J]. J Clin Epidemiol,2011,64(12):1303-1310. DOI:10.1016/j.jclinepi.2011.04.014.
[23] Murphy MK,Black NA,Lamping DL,et al. Consensus development methods,and their use in clinical guideline development[J]. Health Technol Assess,1998,2(3):i-iv,1-88.
[24] Blasco A,Forns X,Carrión JA,et al.Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation[J]. Hepatology,2006,43(3):492-499. DOI:10.1002/hep.21090.
[25] Groszmann RJ,Garcia-Tsao G,Bosch J,et al.Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med,2005,353(21):2254-2261. DOI:10.1056/NEJMoa044456.
[26] Ripoll C,Groszmann R,Garcia-Tsao G,et al.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology,2007,133(2):481-488. DOI:10.1053/j.gastro.2007.05.024.
[27] Ripoll C,Groszmann RJ,Garcia-Tsao G,et al.Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis[J]. J Hepatol,2009,50(5):923-928. DOI:10.1016/j.jhep.2009.01.014.
[28] Bruix J,Castells A,Bosch J,et al.Surgical resection of hepatocellular carcinoma in cirrhotic patients:prognostic value of preoperative portal pressure[J]. Gastroenterology,1996,111(4):1018-1022.
[29] Boleslawski E,Petrovai G,Truant S,et al.Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis[J]. Br J Surg,2012 99(6):855-863. DOI:10.1002/bjs.8753.
[30] Llop E,Berzigotti A,Reig M,et al.Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors[J]. J Hepatol,2012,56(1):103-108. DOI:10.1016/j.jhep.2011.06.027.
[31] Cucchetti A,Cescon M,Golfieri R,et al.Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma[J]. J Hepatol,2016,64(1):79-86. DOI:10.1016/j.jhep.2015.08.025.
[32] Berzigotti A,Reig M,Abraldes JG,et al.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis:a systematic review and meta-analysis[J]. Hepatology,2015,61(2):526-536. DOI:10.1002/hep.27431.
[33] Garcia-Tsao G,Groszmann RJ,Fisher RL,et al.Portal pressure,presence of gastroesophageal varices and variceal bleeding[J]. Hepatology,1985,5(3):419-424.
[34] Kerbert AJ,Chiang FW,van der Werf M,et al. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis:a meta-analysis[J]. Eur J Gastroenterol Hepatol,2017,29(4):380-387. DOI:10.1097/MEG.000000
0000000812.
[35] Merkel C,Bolognesi M,Bellon S,et al.Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices[J]. Gastroenterology,1992,102(3):973-979.
[36] Merkel C,Bolognesi M,Sacerdoti D,et al.The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis[J]. Hepatology,2000,32(5):930-934. DOI:10.1053/jhep.2000.19322.
[37] Silva-Junior G,Baiges A1,Turon F,et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique[J]. Hepatology. 2015,62(5):1584-92. DOI:10.1002/hep.28031.
[38] Berzigotti A,Rossi V,Tiani C,et al.Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension[J]. J Gastroenterol,2011,46(5):687-695. DOI:10.1007/s00535-010-0360-z.
[39] Moitinho E,Escorsell A,Bandi JC,et al.Prognostic value of early measurements of portal pressure in acute variceal bleeding[J]. Gastroenterology,1999,117(3):626-631.
[40] Monescillo A,Martínez-Lagares F,Ruiz-del-Arbol L,et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J]. Hepatology,2004,40(4):793-801. DOI:10.1002/hep.20386.
[41] Zhao JR,Wang GC,Hu JH,et al.Risk factors for early rebleeding and mortality in acute variceal hemorrhage[J]. World J Gastroenterol,2014,20(47):17941-17948. DOI:10.3748/wjg.v20.i47.17941.
[42] Rincon D,Lo Iacono O,Ripoll C,et al.Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis[J]. Aliment Pharmacol Ther,2007,25(7):841-848. DOI:10.1111/j.1365-2036.2007.03258.x.
[43] Schwarzer R,Kivaranovic D,Paternostro R,et al.Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study[J]. Aliment Pharmacol Ther,2018,47(8):1162-1169. DOI:10.1111/apt.14576.
[44] Villanueva C,Aracil C,Colomo A,et al.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding[J]. Gastroenterology,2009,137(1):119-128. DOI:10.1053/j.gastro.2009.03.048.
[45] Hernández-Gea V,Aracil C,Colomo A,et al.Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers[J]. Am J Gastroenterol,2012,107(3):418-427. DOI:10.1038/ajg.2011.456.
[46] Qi XS,Fan DM.Hepatic venous pressure gradient measurement before TIPS for acute variceal bleeding[J]. World J Gastroenterol,2014,20(23):7523-7524. DOI:10.3748/wjg.v20.i23.7523.
[47] García-Pagán JC,Caca K,Bureau C,et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med,2010,362(25):2370-2379. DOI:10.1056/NEJMoa0910102.
[48] Zhang M,Wang G,Zhao L,et al.Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG[J]. Scand J Gastroenterol,2016,51(12):1502-1506. DOI: 10.1080/00365521.2016.1193218.
[49] D'Amico G,Garcia-Pagan JC,Luca A,et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis:a systematic review[J]. Gastroenterology,2006,131(5):1611-24.
[50] Villanueva C,Graupera I,Aracil C,et al.A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis[J]. Hepatology,2017,65(5):1693-1707. DOI:10.1002/hep.29056.
[51] 张明艳,王广川,黄广军,等. 833例次肝静脉压力梯度测定临床分析[J]. 中华肝脏病杂志,2018,26(4):266-270. DOI:10.3760/cma.j.issn.1007-3418.2018.04.007.
[52] Baik SK,Jeong PH,Ji SW,et al.Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis:a randomized comparison[J]. Am J Gastroenterol,2005,100(3):631-635. DOI:10.1111/j.1572-0241.2005.41381.x.
[53] Lim YL,Kim MY,Jang YO,et al.Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure:an open randomized controlled pilot study[J]. Gut Liver,2017,11(5):702-710. DOI:10.5009/gnl16478.
[54] Schwarzer R,Kivaranovic D,Mandorfer M,et al.Randomised clinical study:the effects of oral taurine 6g/day vs placebo on portal hypertension[J]. Aliment Pharmacol Ther,2018,47(1):86-94. DOI:10.1111/apt.14377.
[55] Garcia-Tsao G,Fuchs M,Shiffman M,et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension[J]. Hepatology,2018.In press.DOI:10.1002/hep.30199.
[56] Ratziu V,Goodman Z,Sanyal A.Current efforts and trends in the treatment of NASH[J]. J Hepatol,2015,62(Suppl 1):S65-S75. DOI: 10.1016/j.jhep.2015.02.041.
[57] Wong VW,Adams LA,de Lédinghen V,et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise[J]. Nat Rev Gastroenterol Hepatol,2018,15(8):461-478. DOI:10.1038/s41575-018-0014-9.
[58] Sourianarayanane A,Talluri J,Humar A,et al.Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis[J]. Eur J Gastroenterol Hepatol,2017,29(5):516-523. DOI: 10.1097/MEG.0000000000000825.
[59] Sanyal AJ1,Friedman SL,McCullough AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop[J]. Hepatology,2015,61(4):1392-405. DOI: 10.1002/hep.27678.
[60] Harrison SA,Abdelmalek MF,Caldwell S,et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis [J]. Gastroenterology,2018,S0016-5085(18):34758-34759. DOI:10.1053/j.gastro.2018.07.006.
[61] Tripathi D,Stanley AJ,Hayes PC,et al.U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut,2015,64(11):1680-1704. DOI:10.1136/gutjnl-2015-309262.
[62] 祁小龙. 肝硬化门静脉高压无创时代:我们如何把握[J]. 中华肝脏病杂志,2018,26(4):241-244. DOI:10. 3760/cma. j.issn. 1007-3418. 2018.04.001.
[63] Ferlitsch M,Reiberger T,Hoke M,et al.von Willebrand factor as new noninvasive predictor of portal hypertension,decompensation and mortality in patients with liver cirrhosis[J]. Hepatology,2012,56(4):1439-1447. DOI:10.1002/hep.25806.
[64] Hametner S,Ferlitsch A,Ferlitsch M,et al.The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test[J]. Plos One,2016,11(2):e0149230. DOI:10.1371/journal.pone.0149230.
[65] Sandahl TD,Mcgrail R,Moller HJ,et al.The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis(ELF) score predicts clinically significant portal hypertension in patients with cirrhosis[J]. Aliment Pharmacol Ther,2016,43(11):1222-1231. DOI:10.1111/apt.13618.
[66] Pind ML,Bendtsen F,Kallemose T,et al.Indocyanine green retention test(ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis[J]. Eur J Gastroenterol Hepatol,2016,28(8):948-954. DOI:10.1097/
MEG.0000000000000611.
[67] Wang L,Feng Y,Ma X,et al.Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis[J]. Plos One,2017,12(8):e0182969. DOI: 10.1371/journal.pone.0182969.
[68] Mandorfer M,Scheiner B,Stattermayer AF,et al. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension[J]. Aliment Pharmacol Ther,2018.In press.DOI: 10.1111/apt.14856.
[69] Leeming DJ,Veidal SS,Karsdal MA,et al.Pro-C5,a marker of true type V collagen formation and fibrillation,correlates with portal hypertension in patients with alcoholic cirrhosis[J]. Scand J Gastroenterol,2015,50(5):584-592. DOI:10.3109/00365521.20
996590.
[70] Bruha R,Jachymova M,Petrtyl J,et al.Osteopontin:A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis[J]. World J Gastroenterol,2016,22(12):3441-3450. DOI:10.3748/wjg.v22.i12.3441.
[71] You MW,Kim KW,Pyo J,et al.A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension[J]. Ultrasound Med Biol,2016,43(1):59-68. DOI:10.1016/j.ultrasmedbio.2016.07.025.
[72] Berzigotti A.Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol,2017,67(2):399-411. DOI:10.1016/j.jhep.2017.02.003.
[73] Attia D,Schoenemeier B,Rodt T,et al.Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension[J]. Ultraschall Med,2015,36(6):603-610. DOI: 10.1055/s-0041-107971.
[74] Deng H,Qi X,Zhang T,et al.Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases:a meta-analysis[J]. Expert Rev Gastroenterol Hepatol,2017,12(1):91-98. DOI:10.1080/17474124.2018.1412257.
[75] Thiele M,Madsen BS,Procopet B,et al.Reliability criteria for liver stiffness measurements with real-time 2d shear wave elastography in different clinical scenarios of chronic liver disease[J]. Ultraschall Med,2017,38(6):648-654. DOI: 10.1055/s-0042-
108431.
[76] Procopet B,Berzigotti A,Abraldes JG,et al.Real-time shear-wave elastography:applicability,reliability and accuracy for clinically significant portal hypertension[J]. J Hepatol,2015,62(5):1068-1075. DOI:10.1016/j.jhep.2014.12.007.
[77] Song J,Huang J,Huang H,et al.Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension:a meta-analysis[J]. Clin Res Hepatol Gastroenterol,2018,42(3):216-226. DOI:10.1016/j.clinre.2017.11.002.
[78] Takuma Y,Nouso K,Morimoto Y,et al.Portal Hypertension in patients with liver cirrhosis:diagnostic accuracy of spleen stiffness[J]. Radiology,2016,279(2):609-619. DOI:10.1148/radiol.2015150690.
[79] Zykus R,Jonaitis L,Petrenkien V,et al.Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease:a prospective cohort study[J]. BMC Gastroenterol,2015,24:183. DOI: 10.1186/s12876-015-0414-z.
[80] Elkrief L,Rautou PE,Ronot M,et al.Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis[J]. Radiology,2015,275(2):589-598. DOI: 10.1148/radiol.14141210.
[81] Jansen C,Bogs C,Verlinden W,et al.Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension:a prospective multicentre study[J]. Liver Int,2017,37(3):396-405. DOI:10.1111/liv.13243.
[82] Elkrief L,Ronot M,Andrade F,et al.Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis[J]. Aliment Pharmacol Ther,2018,47(5):621-630. DOI:10.1111/apt.14488.
[83] Song J,Ma Z,Huang J,et al. Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases:a meta-analysis[J]. Eur Radiol,2018.In press. DOI:10.1007/s00330-018-5478-z.
[84] Piecha F,Mandorfer M,Peccerella T,et al. Pharmacological decrease of liver stiffness is pressure-related and predicts long term clinical outcome [J]. Am J Physiol Gastrointest Liver Physiol,2018.In press.DOI:10.1152/ajpgi.00392.2017.
[85] Liu F,Ning Z,Liu Y,et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701):a prospective multicenter study[J]. EBioMedicine,2018,pii:S2352-3964(18)30381-5. DOI:10.1016/j.ebiom.2018.09.023.
[86] Palaniyappan N,Cox E,Bradley C,et al.Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol,2016,65:1131-1139. DOI: 10.1016/j.jhep.2016.07.021.
[87] Chouhan MD,Mookerjee RP,Bainbridge A,et al.Caval subtraction 2D phase-contrast MRI to measure total liver and hepatic arterial blood flow: proof-of-principle,correlation with portal hypertension severity and validation in patients with chronic liver disease[J]. Invest Radiol,2017,52(3):170-176. DOI: 10.1097/RLI.0000000000000328.
[88] Gharib AM,Han MAT,Meissner EG,et al.Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease[J]. Biomed Res Int,2017,2017:2067479. DOI: 10.1155/2017/2067479.
[89] Qi X,Li Z,Huang J,et al.Virtual portal pressure gradient from anatomic CT angiography[J]. Gut,2015,64(6):1004-1005. DOI: 10.1136/gutjnl-2014-308543.
[90] Lee DH,Ahn JH,Chung JW,et al. Varices on CT is surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patient[J]. J Gastroenterol Hepatol,2018.In press.DOI:10.1111/jgh.14319.
[91] Kim MY,Baik SK,Park DH,et al.Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis:a prospective nonrandomized study[J]. Liver Int,2007,27(8):1103-1110. DOI: 10.1111/j.1478-3231.2007.01526.x.
[92] Bolognesi M,Sacerdoti D,Merkel C,et al.Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler[J]. Ultrasound Med Biol,2001,27(7):901-907.
[93] Lee CM,Jeong WK,Lim S,et al.Diagnosis of clinically significant portal hypertension in patients with cirrhosis:splenic arterial resistive index versus liver stiffness measurement[J]. Ultrasound Med Biol,2016,42(6):1312-1320. DOI: 10.1016/j.ultrasmedbio.2016.01.026.
[94] Maruyama H,Yokosuka O.Ultrasonography for noninvasive assessment of portal hypertension[J]. Gut Liver,2017,11(4):464-473. DOI:10.5009/gnl16078.
[95] Maruyama H,Shiha G,Yokosuka O,et al.Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography[J]. Hepatol Int,2016,10(2):267-276. DOI:10.1007/s12072-015-9670-9.
[96] Eisenbrey JR,Dave JK,Halldorsdottir VG,et al.Chronic liver disease:noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient[J]. Radiology,2013,268(2):581-588. DOI:10.1148/radiol.13121769.
[97] Amat-Roldan I,Berzigotti A,Gilabert R,et al.Assessment of hepatic vascular network connectivity with automated graph analysis of dynamic contrast-enhanced US to evaluate portal hypertension in patients with cirrhosis:a pilot study[J]. Radiology,2015,277(1):268-276. DOI:10.1148/radiol.2015141941.
[98] Berzigotti A,Piscaglia F,Amat-Roldan I,et al.Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound:the CLEVER study[J]. J Hepatol, 2018,68:S76-S77.
[99] Talaki E,Schaffellner S,Kniepeiss D,et al.CT perfusion imaging of the liver and the spleen in patients with cirrhosis:Is there a correlation between perfusion and portal venous hypertension[J]. Eur Radiol,2017,27(10):4173-4180. DOI:10.1007/s00330-017-4788-x.
[100] Asenbaum U,Ba-Ssalamah A,Mandorfer M,et al.Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance:Diagnostic and Prognostic Implications[J]. Invest Radiol,2017,52(8):462-469. DOI:10.1097/RLI.0000000000000366.
[101] Liu J,Zhang H,Xia Y,et al.Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma:a systematic review and meta-analysis[J]. HPB(Oxford),2018,DOI:10.1016/j.hpb.2018.07.005.
[102] Lim C,Osseis M,Lahat E,et al. Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension:interim analysis of an open prospective study [J]. Surg Endosc,2018. In press. DOI:10.1007/s00464-018-6347-1.

Consensus on clinical application of hepatic venous pressure gradient in China (2018)

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[3]	Zhang Yunfeng, Wei Ailin, Huang Jin, et al. Effect of modified Sugiura’s operation on portal hemodynamics in cirrhotic patients with portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 553-556.
[4]	Wang Wensheng, Chen Dongfeng, Wen Liangzhi. Highlights in portal hypertensive gastropathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 601-604.
[5]	Chen Junbang, Li Jian, Liang Jundi, Quan Yi, Li Guangqing, Yang Kai. Application of transjugular intrahepatic portosystemic shunt in the treatment of cirrhotics with portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 228-231.
[6]	Jugu Munai, Wang Rongdong, Hu Ge, et al. Outcomes of laparoscopic esophagogastric devascularization and splenectomy or preserving spleens in patients with cirrhotic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 601-604.
[7]	Chen Shiyao, Huang Xiaoquan, Ceng Xiaoqing. Etiology and diagnosis of portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 321-324.
[8]	Ji Yuan. Clinical and histopathological features of patients with idiopathoc noncirrhotic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 325-328.
[9]	Zhang Ming, Zhuge Yuzheng, Zou Xiaoping. Application of interventional techniques in patients with unknown etiologic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 329-331.
[10]	Yang Kaiqi, Chen Shiyao. Prognosis of patients with idiopathic portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 332-335.
[11]	Jian Yourong, Chen Shiyao. Cardiac functions in patients with portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 336-339.
[12]	Li Liangliang, Ma Jinliang, Jia Weidong, et al. Clinical application of enhanced recovery after surgery program in patients with portal hypertention underwent pericardial devascularization with splenectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 368-371.
[13]	Li Xiaodong, Zheng Bebo, Liu Shan. Efficacy of splenectomy and pericardial devascularizatio in patients with liver cirrhosis and portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 289-290.
[14]	Wang Shuai, Qi Xiaolong. Classification and diagnosis of portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 14-17.
[15]	Liu Qin, Luo Yanli, Xiao Fengming. Prognostic factors after splenectomy and portal azyqous disconnection in patients with hepatitis B cirrhosis and portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 769-770.